Drug Profile

S 268019

Alternative Names: Coronavirus vaccine - UMN Pharma; COVGOZE; recombinant protein vaccine - UMN Pharma; S-268019; SARS-CoV-2 vaccine - UMN Pharma

Latest Information Update: 01 Jul 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator UMN Pharma
Developer Shionogi
Class COVID-19 vaccines; Peptide vaccines; Recombinant proteins; Synthetic vaccines; Viral vaccines
Mechanism of Action Immunostimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

24 Jun 2024 Registered for COVID-2019 infections (Prevention) in Japan (IM) - First global approval
19 Jul 2023 Shionogi completes a phase III trial in COVID-2019 infections (Prevention) in Vietnam (IM) (NCT05212948)
16 Dec 2022 Shionogi completes phase-I/II trial in COVID-2019 infections (Prevention) in Japan (IM, Injection) before December 2022 (jRCT2051200092)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com